Benzinga··Bamboo WorksChinese Cancer Screener Bets on Hong Kong IPO Despite Biotech Downturn
Wuhan Ammunition Life-tech pursues Hong Kong listing with doubled revenue but widened losses, facing 147x P/S valuation amid sector turmoil.
NHZHYBNRIPOHong Kong Stock Exchange